Paper Details

  1. Home
  2. Paper Details

Eltrombopag in the Treatment of Immune Thrombocytopenia: Two-Center Experience from Istanbul.

Author: AydinDemet, Celik KamaciSule, CiftciUgur, DemirelNaciye, DoganEsma Evrim, ElverdiTugrul, ErenRafet, Turan ErkekEsra

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study retrospectively evaluated the efficacy, safety, and side-effect profile of eltrombopag treatment for chronic ITP. The overall response rate was 87%, with a complete response rate of 78.3%. While eltrombopag is a very effective treatment option, long-term side effects are still being studied.
Paper Details　
Original Abstract of the Article :
Immune Thrombocytopenia (ITP) is a disease caused by autoantibodies forming against platelets and T cell dysregulation and is characterized by platelet count falling below 100&#8201;&#215;&#8201;10<sup>9</sup>/L. Corticosteroids remain as the first-line of treatment, but in the light of recent devel...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001770/

データ提供：米国国立医学図書館（NLM）

Eltrombopag in the Treatment of Immune Thrombocytopenia: A Two-Center Experience

This study sheds light on the efficacy and safety of [eltrombopag] in treating [immune thrombocytopenia (ITP)], a condition marked by a dangerously low platelet count. The researchers retrospectively analyzed data from two centers in Istanbul, evaluating the outcomes of [eltrombopag treatment] in chronic ITP patients. They found that [eltrombopag demonstrated significant efficacy in raising platelet counts] and showed a favorable safety profile, offering a promising treatment option for patients with [steroid-dependent or refractory ITP].

Eltrombopag: A Potential Game Changer for ITP Management

The success rate of [eltrombopag] in treating ITP, as revealed by this study, suggests a potential shift in the management of this challenging condition. The findings provide compelling evidence for the use of [eltrombopag] as a valuable tool for [increasing platelet counts] and improving the lives of ITP patients.

The Importance of Ongoing Research

While this study offers promising insights, it is crucial to recognize that [further research is needed to fully understand the long-term effects of eltrombopag]. Like exploring an uncharted desert landscape, ongoing research is necessary to uncover the full potential and implications of this promising treatment option.

Dr.Camel's Conclusion

This study reveals the potential of eltrombopag as a beacon of hope in the desert of ITP treatment. It offers a promising alternative to traditional therapies, providing a potential path to improved outcomes for patients. However, ongoing research is essential to fully explore the vast desert of its long-term effects and ensure its safe and effective application in the future.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-04-02
Further Info :

Pubmed ID

35496971

DOI: Digital Object Identifier

PMC9001770

Related Literature

Article Analysis
・Side Effects of eltrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.